Disitamab Vedotin vs Trastuzumab Deruxtecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline

Disitamab Vedotin

Marketed by RemeGen Co., Ltd. and partners

Phase 2 in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT04311034 · Phase 1/2 · completed

The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.

Next expected readout: June 2027 · NCT06734182 (registry estimate)

No aligned efficacy figure on record for this race.

Trastuzumab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in Non-Small Cell Lung Cancerantibody-drug conjugate
Weak signal

NCT03505710 · Phase 2 · terminated

Participants were placed in cohorts by HER2 status and dose without randomization, nobody was blinded to treatment, and there was no comparison arm. Response rates were read by an independent central reviewer but are reported for each cohort on its own.

Next expected readout: December 2026 · NCT06250777 (registry estimate)

Reported efficacy

Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70) (not_applicable)

Result source: NCT04644237

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDisitamab VedotinTrastuzumab Deruxtecan
PFS, median—Not reported9.5b6.4 mg/kg · n 50NCT04644237
1 other result
  • 9.7 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237
OS, median—Not reported17.9b6.4 mg/kg · n 50NCT04644237
1 other result
  • 19 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237
ORR—Not reported56%b6.4 mg/kg · n 50NCT04644237
3 other results
  • 50% 5.4 mg/kg · n 102 · Phase 2 · primary NCT04644237
  • 56% 6.4 mg/kg · n 50 · Phase 2 · secondary NCT04644237
  • 46.1% 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237
Duration of response, median—Not reported12.9b6.4 mg/kg · n 28NCT04644237
1 other result
  • 11.1 5.4 mg/kg · n 47 · Phase 2 · secondary NCT04644237

PFS, median

Disitamab Vedotin
—Not reported
Trastuzumab Deruxtecan
9.5b6.4 mg/kg · n 50NCT04644237
1 other result
  • 9.7 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237

OS, median

Disitamab Vedotin
—Not reported
Trastuzumab Deruxtecan
17.9b6.4 mg/kg · n 50NCT04644237
1 other result
  • 19 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237

ORR

Disitamab Vedotin
—Not reported
Trastuzumab Deruxtecan
56%b6.4 mg/kg · n 50NCT04644237
3 other results
  • 50% 5.4 mg/kg · n 102 · Phase 2 · primary NCT04644237
  • 56% 6.4 mg/kg · n 50 · Phase 2 · secondary NCT04644237
  • 46.1% 5.4 mg/kg · n 102 · Phase 2 · secondary NCT04644237

Duration of response, median

Disitamab Vedotin
—Not reported
Trastuzumab Deruxtecan
12.9b6.4 mg/kg · n 28NCT04644237
1 other result
  • 11.1 5.4 mg/kg · n 47 · Phase 2 · secondary NCT04644237
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Disitamab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Disitamab Vedotin: 0 of 4 rows · Trastuzumab Deruxtecan: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTrastuzumab Deruxtecan
Dropout rate
n/a: no completion milestone6.4 mg/kga
NCT04644237 · Phase 2
show 1 more result
n/a: no completion milestone5.4 mg/kg
NCT04644237 · Phase 2
Discontinued due to AEs
38%6.4 mg/kga
NCT04644237 · Phase 2
show 1 more result
17.6%5.4 mg/kg
NCT04644237 · Phase 2
Serious AEs
52%6.4 mg/kga
NCT04644237 · Phase 2
show 1 more result
41.6%5.4 mg/kg
NCT04644237 · Phase 2
Most frequent reported AEs
6.4 mg/kga
nausea 82%
decreased appetite 50%
anaemia 48%
NCT04644237 · Phase 2
show 1 more result
5.4 mg/kg
nausea 68.3%
anaemia 40.6%
decreased appetite 40.6%
NCT04644237 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Trastuzumab Deruxtecan

ORR 56% (n=50)6.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT04644237 · Phase 2
show 3 more results
56% (n=50)6.4 mg/kg
NCT04644237 · Phase 2
50% (n=102)5.4 mg/kg
NCT04644237 · Phase 2
46.1% (n=102)5.4 mg/kg
NCT04644237 · Phase 2
Duration of Response 12.9 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
11.1 months5.4 mg/kg
NCT04644237 · Phase 2
Disease Control 88% (n=50)6.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
90.2% (n=102)5.4 mg/kg
NCT04644237 · Phase 2
PFS 9.5 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
9.7 months5.4 mg/kg
NCT04644237 · Phase 2
Overall Survival 17.9 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
19 months5.4 mg/kg
NCT04644237 · Phase 2
EORTC QLQ-C30 15.63 score6.4 mg/kg
absolute change · score
No placebo or comparator arm
QLQ-C30: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
show 1 more result
-1.11 score5.4 mg/kg
QLQ-C30: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
EORTC QLQ-LC13 -29.17 score6.4 mg/kg
absolute change · score
No placebo or comparator arm
QLQ-LC13: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
show 1 more result
-2.38 score5.4 mg/kg
QLQ-LC13: Change from Baseline 40-Day Follow-up
NCT04644237 · Phase 2
Time to Deterioration QLQ-C30 9.3 months6.4 mg/kg
time to event · months
No placebo or comparator arm
NCT04644237 · Phase 2
show 1 more result
8.6 months5.4 mg/kg
NCT04644237 · Phase 2

HER2-Positive Breast Cancer

Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline

Disitamab Vedotin

Marketed by RemeGen Co., Ltd. and partners

Phase 2/3 in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT03500380 · Phase 2/3 · status unknown

This trial randomized 301 patients with HER2-positive metastatic breast cancer to disitamab vedotin or an active comparator regimen (lapatinib plus capecitabine), with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07366840 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) as Assessed by an IRC (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months): Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). (met)

Result source: NCT03500380

Trastuzumab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in HER2-Positive Breast Cancerantibody-drug conjugate
Partial signal

NCT03523585 · Phase 3 · completed

The 608-participant trial was randomized and actively controlled, with progression-free survival assessed by blinded independent central review as the primary clinical endpoint. The primary comparison was statistically significant in favor of trastuzumab deruxtecan, but treatment assignment was open-label rather than double-blinded, supporting a moderate evidence grade.

Next expected readout: January 2027 · NCT06797622 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) (met)

Result source: NCT03523585

Results for HER2-Positive Breast Cancer

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Disitamab Vedotin
Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). NCT03500380 · Phase 2/3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Trastuzumab Deruxtecan

PFS 17.8 months
time to event · months
No placebo or comparator arm
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
16.7 months
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival 39.2 months
time to event · months
No placebo or comparator arm
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
13.3 months
NCT04420598 · Phase 2 · registry result, not featured evidence
ORR 69.7% (n=406)
responder rate · % of participants
No placebo or comparator arm
BICR
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Duration of Response 19.6 months
time to event · months
No placebo or comparator arm
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
PFS-16 12.5% (n=8) @ 16wk
event count · % of participants
No placebo or comparator arm
With PFS at 16 weeks
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
ORR 70% (n=10)
event count · % of participants
No placebo or comparator arm
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 2 more results
55.6% (n=9)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
50% (n=6)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
Clinical Benefit 87.5% (n=8)
event count · % of participants
No placebo or comparator arm
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
show 4 more results
60% (n=10)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
66.7% (n=9)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
50% (n=6)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 3 Participants as posted
71.4% (n=7)*
Yes
NCT04420598 · Phase 2 · registry result, not featured evidence · converted to % from 5 Participants as posted
Available safety results

Trastuzumab Deruxtecan

Dropout rate
76.8%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
62.5%Cohort 1
NCT04420598 · Phase 2 · registry result, not featured evidence
70%Cohort 2
NCT04420598 · Phase 2 · registry result, not featured evidence
88.9%Cohort 3
NCT04420598 · Phase 2 · registry result, not featured evidence
33.3%Cohort 4
NCT04420598 · Phase 2 · registry result, not featured evidence
71.4%Cohort 5
NCT04420598 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
18.2%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
—Cohort 1
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 2
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 3
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 4
NCT04420598 · Phase 2 · registry result, not featured evidence
—Cohort 5
NCT04420598 · Phase 2 · registry result, not featured evidence
Serious AEs
25.5%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
0%Cohort 1
NCT04420598 · Phase 2 · registry result, not featured evidence
10%Cohort 2
NCT04420598 · Phase 2 · registry result, not featured evidence
55.6%Cohort 3
NCT04420598 · Phase 2 · registry result, not featured evidence
16.7%Cohort 4
NCT04420598 · Phase 2 · registry result, not featured evidence
57.1%Cohort 5
NCT04420598 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
nausea 72.3%
alopecia 37.1%
vomiting 37.1%
NCT03523585 · Phase 3 · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 5 more results
fatigue 75%
constipation 62.5%
nausea 50%
NCT04420598 · Phase 2 · registry result, not featured evidence
fatigue 90%
nausea 70%
aspartate aminotransferase increased 50%
NCT04420598 · Phase 2 · registry result, not featured evidence
anaemia 44.4%
fatigue 44.4%
neutropenia 44.4%
NCT04420598 · Phase 2 · registry result, not featured evidence
fatigue 83.3%
nausea 50%
anaemia 33.3%
NCT04420598 · Phase 2 · registry result, not featured evidence
nausea 57.1%
anaemia 42.9%
fatigue 42.9%
NCT04420598 · Phase 2 · registry result, not featured evidence

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline

Disitamab Vedotin

Marketed by RemeGen Co., Ltd. and partners

Phase 3 in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT04400695 · Phase 3 · recruiting

This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry.

Next expected readout: December 2026 · NCT05831878 (registry estimate)

Reported efficacy

RP2D (Estimated 2 year): Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months (not_applicable)

Result source: NCT03052634

Trastuzumab Deruxtecan

Marketed by Daiichi Sankyo and partners

Approved in HR+/HER2- Metastatic Breast Cancerantibody-drug conjugate
Partial signal

NCT04494425 · Phase 3 · active, not recruiting

The trial was large and randomized, with an active chemotherapy comparator and a hard clinical primary endpoint of progression-free survival, which was met: median PFS was 13.2 versus 8.1 months, with HR 0.62 and p<0.0001. However, treatment assignment was not blinded, so despite the strong randomized result this is considered moderate evidence rather than strong evidence.

Next expected readout: November 2026 · NCT06048718 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) (met)

Result source: NCT04494425

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDisitamab VedotinTrastuzumab Deruxtecan
PFS, median—Trial running · NCT05904964—Trial running · NCT04494425
OS, median—Trial running · NCT05904964—Trial running · NCT04494425
ORR—Trial running · NCT05904964—Trial running · NCT04494425
Clinical benefit rate—Trial running · NCT05904964—Trial running · NCT04494425

PFS, median

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab Deruxtecan
—Trial running · NCT04494425

OS, median

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab Deruxtecan
—Trial running · NCT04494425

ORR

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab Deruxtecan
—Trial running · NCT04494425

Clinical benefit rate

Disitamab Vedotin
—Trial running · NCT05904964
Trastuzumab Deruxtecan
—Trial running · NCT04494425
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Disitamab Vedotin
Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months NCT03052634 · Phase 1/2 · design grade: weak · publication or press release
Trastuzumab Deruxtecan
Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) NCT04494425 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1) NCT03734029 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · Trastuzumab Deruxtecan's landscape